Non-Hodgkin lymphoma, unspecified. Non-Hodgkin lymphoma, unspecified
Conditions
Interventions
Intervention 1: R-CHOP-21:intravenous cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 (maximum dose 2 mg), and rituximab (MabThera®) 375 mg/m2 on day 1, and oral prednisolone 1
Treatment - Drugs
R-CHOP-21:intravenous cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 (maximum dose 2 mg), and rituximab (MabThera®) 375 mg/m2 on day 1, and oral prednisolone 100 mg/m2 on days
R-CHOP-14 group: intravenous cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 2 mg, rituximab(MabThera®) 375 mg/m2 on day 1, and oral prednisolone 100 mg on days 1–5, administered every 1
Sponsors
Vice chancellor for research, Kermanshah University Of Medical Sciences and Health Services
Eligibility
Sex/Gender
All
Age
16 Years to 82 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age; sex; type of NHL; subtype; Ki-67 index; organomegaly; lymphadenopathy; radiotherapy; anatomic sites of NHL; recurrence Exclusion criteria: cardiovascular; renal; hepatic disease (hepatitis B or hepatitis C; T-cell lymphoma;patients with initial neutrophil count <1.5×109 per L; initial platelet count <100×109 per L
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival. Timepoint: 2 and 5 years. Method of measurement: Observtion. | — |
Secondary
| Measure | Time frame |
|---|---|
| Neutropenia. Timepoint: every 14 days and every 21 days. Method of measurement: Experimental. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasoud Sadeghi
Kermanshah University of Medical Sciences
Outcome results
None listed